Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronal Mucopolysaccharidosis II: an Integrated Analysis of Preclinical and Clinical Data

Roberto Giugliani1, Ana Maria Martins2, Torayuki Okuyama3, Yoshikatsu Eto1, Norio Sakai1, Kimitoshi Nakamura1, Hideto Morimoto1, Kohtaro Minami1, Tatsuyoshi Yamamoto1, Mariko Yamaoka1, Toshiaki Ikeda1, Sairei So7, Kazunori Tanizawa1, Hiroyuki Sonoda7, Mathias Schmidt7 and Yuji Sato7*

1 Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul; rgiugliani@hcpa.edu.br
2 Universidade Federal de São Paulo ni.martins10@gmail.com
3 National Centre for Child Health and Development; okuyama-t@ncchd.go.jp
4 Advanced Clinical Research Centre & Asian Lysosome Storage Disorder Centre, Institute of Neurological Disorders; yosh@sepia.ocn.ne.jp
5 Osaka University Graduate School of Medicine; norio@sahs.med.osaka-u.ac.jp
6 Kumamoto University Graduate School of Medical Science; nakamura@kumamoto-u.ac.jp
7 JCR Pharmaceuticals; morimoto-h@jcrpharm.co.jp, minami-k@jcrpharm.co.jp, t-yamamoto@jcrpharm.co.jp, m-yamaoka@jcrpharm.co.jp, ikeda-t@jcrpharm.co.jp, sou-st@jcrpharm.co.jp, tanizawa-k@jcrpharm.co.jp, sonoda-h@jcrpharm.co.jp, mschmidt@jcrpharm.co.jp
* Correspondence: sato-yuji@jcrpharm.co.jp, Tel.: +81-797-32-8591

Abstract: (179 < 200)

Enzyme replacement therapy (ERT) improves the somatic manifestations in mucopolysaccharidoses (MPS). However, because intravenously administered enzymes cannot cross the blood brain barrier (BBB), ERT is ineffective against the progressive neurodegeneration and resultant severe central nervous system (CNS) symptoms observed in patients with neuronal MPS. Attempts to surmount this problem have been made with intrathecal and intracerebroventricular ERT intend to achieve CNS effects, but the burdens on patients are inimical to long-term multiple administrations. However, after pabinafusp alfa, a human iduronate-2-sulfatase fused with a BBB-crossing anti-transferrin receptor antibody, showed both central and peripheral efficacy in mice model, subsequent clinical trials in a total of 62 patients with MPS-II (Hunter syndrome) in Japan and Brazil substantiated this dual efficacy and provided an acceptable safety profile. To date, pabinafusp alfa is the only approved intravenous ERT effective against both the somatic and CNS symptoms of patients with MPS-II. This article summarizes the hitherto obtained preclinical and clinical evidence associated with this drug, and discusses the preclinical, translational and clinical challenges of evaluating, ameliorating and preventing the neurodegeneration in patients with MPS-II.
Keywords: neuronopathic mucopolysaccharidosis; Hunter syndrome; mucopolysaccharidosis II, iduronate-2-sulfatase; enzyme replacement therapy; neurodegeneration; neurocognitive impairment; pabinafusp alfa; blood brain barrier

(List three to ten pertinent keywords specific to the article yet reasonably common within the subject discipline.)

1. Introduction

A number of treatment modalities have been developed to the benefit of patients with mucopolysaccharidoses (MPS). Chief among them is enzyme replacement therapy (ERT) that compensates for the specific genetic deficiencies of enzymes and thereby ameliorates most of the somatic symptoms caused by the systemic accumulation of glycosaminoglycans (GAGs) and related events [1,2]. However, as large molecules cannot penetrate the blood brain barrier (BBB), intravenously (IV) administered enzymes are prevented from reaching the brain parenchyma and catabolizing the GAGs therein. The GAG accumulation that then form in the central nervous system (CNS) initiates a complex neurodegenerative process [3] that culminates in multifaceted progressive CNS symptoms in patients with MPS I, II, III, and VII (also known as neuronopathic MPS), often leading to early mortality [4].

Various efforts have been made to address the debilitating CNS manifestations in patients with neuronopathic MPS, including hematopoietic stem cell transplantation, gene therapy, and ERT via intrathecal (IT) and intracerebroventricular (ICV) administration. IT and ICV ERT are intended to circumvent the BBB and deliver enzymes directly into the brain, and they have been reported to show positive CNS efficacy [5-7]. However, they invariably involve invasive procedures that are not conducive to long-term repeated administrations, and because they are ineffective against the somatic symptoms, patients are faced with the additional onus of concomitant IV ERT.

Other attempts to address the CNS symptoms have been made by utilizing the insulin [8, 9] and transferrin [10] receptors located on the cerebrovascular endothelial cells, so that the modified enzymes can traverse the BBB through these receptors and exert their effects in the brain parenchyma.

Pabinafusp alfa (JR-141), developed by JCR Pharmaceuticals, consists of human iduronate-2-sulfatase (IDS), the enzyme that is deficient in patients with MPS-II (Hunter syndrome), fused to the C-terminus of the heavy chain of an anti-human transferrin receptor
(hTfR) antibody. Its successful delivery across the BBB into the CNS by way of TfR-mediated transcytosis has been demonstrated in animal models, along with the resultant effects of decreasing heparan sulfate (HS) accumulations in the brain [11, 12]. These promising preclinical data have prompted the first-in-human phase I/II study in Japan involving patients with MPS-II, which also produced encouraging results [13]. A subsequent phase II study in Brazil [14] and a phase II/III study in Japan [15] have further substantiated the somatic / peripheral and central efficacy of pabinafusp alfa, leading to its regulatory approval for general use in Japan in March 2021 as the first BBB-crossing ERT. This article reports an integrated analysis of the hitherto accumulated preclinical and clinical data, including the latest long-term efficacy and safety data from the ongoing extension studies in the two countries, and some of the methodological and scientific challenges that had to be overcome in preclinical and clinical evaluations of the drug’s efficacy against complex progressive neurodegeneration.

2. Results

2.1. Preclinical safety and efficacy results

2.1.1. Mechanism of action: cellular uptake and BBB penetration

Pabinafusp alfa has mannose-6-phosphate (M6P) residues that possess binding affinity against M6P receptors, and it is taken up by target cells through M6P receptor-mediated endocytosis; the TfR-mediated pathway also facilitates cellular uptake [11]. The major advantage of pabinafusp alfa is the fusion of anti-hTfR antibody to IDS, which gives it the ability to pass the BBB to reach CNS tissues [17, 18]. Figure 1 shows the results of an immunohistochemical analysis in which pabinafusp alfa, when administered intravenously to cynomolgus monkeys and hTfR-expressing mice, was found in neuronal cells in the different brain regions [11]. These results indicate that, thanks to its TfR-binding ability, pabinafusp alfa reaches the brain parenchyma by crossing the BBB via TfR-mediated transcytosis.
Figure 1. Delivery of pabinafusp alfa to neuronal cells in the brain of a cynomolgus monkey. Pabinafusp alfa was intravenously administered to cynomolgus monkey at a dose of 5 mg/kg, and the brains were resected at 8 h after the administration. Arrows in upper panels indicate pyramidal cells in the hippocampus (left) and Purkinje cells in the cerebellum (right). Lower panels show negative control (administered control IgG which does not cross the BBB). Scale bars, 20 mm.

2.1.2. Substrate reduction

The primary pathogenesis of MPS II is systemic intracellular accumulation of GAGs due to inherited dysfunction or deficiency of IDS [20, 21]. Therefore, the substrate-reducing activity of pabinafusp alfa was evaluated as an indicator of its pharmacological efficacy in an MPS II mouse model using Ids deficient mice expressing hTfR[11]. Repeated intravenous administration of pabinafusp alfa dose-dependently reduced the accumulations of GAGs (i.e. HS and dermatan sulfate (DS)) in the tissues and organs, including the brain [22]. HS concentration in the brain rapidly decreased before the maximum reduction was achieved at around 10 weeks of dosing, and continued to decrease moderately thereafter (Figure 2). These results clearly indicate that intravenously administered pabinafusp alfa is efficacious against pathogenic accumulation of GAGs, not only in the peripheral tissues and organs but also in the brain. This is in sharp contrast to the conventional intravenous ERT with idursulfase, which does not affect HS concentration in the brain at all (Figure 2).
Figure 2. Substrate reducing efficacy of pabinafusp alfa in the brain of MPS II mice. Pabinafusp alfa was intravenously administered to the mice at a dose of 2 mg/kg once per week for 1, 4, 8, 12, or 36 weeks. The dose of idursulfase was 0.5 mg/kg/week. Data are from independent experiments (mean with S.D. bars, n = 3-5).

2.1.3. Prevention of neuroinflammation and subsequent neurodegeneration

The neurodegenerative processes in MPS II mice were preceded by activation of glial cells [23, 24]. For instance, the intensity of glial fibrillary acidic protein (GFAP) signals increased in the astroglia, as did the number of CD68-positive microglia in the brain cortex (Figure 3). These histopathological changes were suppressed by chronic intravenous treatment with pabinafusp alfa (Figure 3). The relief from neuroinflammation afforded by pabinafusp alfa further prevented morphological abnormalities and neuronal death in the brain of untreated MPS II mice (Figure 3), whereas idursulfase was ineffective against these pathological changes in the brain [22].
Figure 3. Prevention of neuroinflammation and neurodegeneration by pabinafusp alfa in MPS II mouse brains. Specimens from the brain cortex were stained with GFAP (top), CD68 (middle), and hematoxylin/eosin (bottom). Data are from the 36-week study. Arrows indicate vacuolation of neuronal cells. Scale bars, 50 μm.

2.1.4. Prevention of neurocognitive abnormalities

In MPS II mice, progressive neurocognitive impairments manifest themselves as loss of spatial learning ability that can be assessed with the Morris water maze test [25]. When normal healthy mice were subjected to the test, the time to reach the platform (goal latency) became shorter day by day, whereas untreated MPS II mice showed difficulty learning how to reach the platform [22] (Figure 4). The mice receiving chronic treatment with pabinafusp alfa maintained their spatial learning ability, unlike the wild-type animals (Figure 4). Idursulfase failed to prevent the loss of learning ability, so the attenuation of neurocognitive abnormalities observed in the pabinafusp alfa-treated MPS II mice can be primarily attributed to the clearance of HS deposited in the brain. In other words, HS concentration in the brain can be viewed as a good predictor of neurodegeneration as well as a marker of drug efficacy in patients with neuronopathic MPS II.
Figure 4. Maintenance of spatial learning abilities in MPS II mice receiving chronic treatment with pabinafusp alfa. After 36 weeks of treatment, spatial learning ability was assessed with the Morris water maze test. The time to reach the platform (goal latency) was measured 3 times per day and the means were calculated within each day for individual animals. Values are presented as the mean with S.E. for each group (n = 12-15). Paired t-test, **P < 0.01 (Day 1 vs. Day 5). EW, every week; EoW, every other week.

2.1.5. Identification of biomarker for CNS efficacy

Thanks to the weakness of the barrier between the brain parenchyma and the cerebrospinal fluid (CSF) [26], HS concentrations in the brain are considered to be directly correlated with those in the CSF, as demonstrated by the high correlations we found between the intracerebral and CSF HS concentrations in the MPS II mice treated with pabinafusp alfa (Figure 5). Thus, HS concentrations in the CSF are a useful and practical surrogate biomarker to monitor drug efficacy in patients with neuronopathic MPS II, because the HS concentrations in the brain cannot be measured in clinical settings.
Figure 5. Correlation between concentrations of HS in the brains and the CSF of MPS II mice treated with pabinafusp alfa. Results from studies of single-dose, 4-week, 8-week, 12-week, and 36-week treatments are included.

2.2 Preclinical safety results

In vitro assay systems were used to comprehensively evaluate the preclinical safety of pabinafusp alfa in cynomolgus monkeys. Since pabinafusp alfa contains entire IgG structure in its molecule, safety evaluation needs to involve antibody-associated functions, such as effector functions relevant to cytotoxicity[27]. In this regard, the potential effects of pabinafusp alfa on antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) were examined with TfR-expressing hematopoietic cells, which elicited neither ADCC nor CDC [19]. Consistent with these findings, chronic treatment with the drug did not cause anemia in cynomolgus monkeys. In addition, the binding of pabinafusp alfa with TfR did not interfere with transferrin-TfR interaction. Repeat-dose toxicity studies in cynomolgus monkeys showed no significant toxicological changes at weekly doses of up to 30 mg/kg of pabinafusp alfa, without affecting the iron metabolism. Overall, the preclinical safety studies suggested no significant safety concerns that could be considered clinically relevant to patients with MPS II.

2.3 Clinical results

2.3.1. Clinical efficacy data
1) Substrate reduction in the CSF

On the basis of the preclinical findings (2.1.4), HS levels in the CSF were stipulated as the primary efficacy surrogate endpoint in the three clinical trials conducted so far. Figure 6 shows the baseline HS levels in the CSF of the 29 patients in the phase I/II and III studies in Japan, which correlated with the disease severity that are ascribed to each patient by his physicians based on their clinical judgment. The HS levels in the CSF serves as an accurate indicator of neurodegenerative severity as well as a predictor of clinical outcomes in terms of CNS manifestations. Most patients with attenuated subtypes show HS levels below 4000 ng/ml, which may well indicate that this level is the threshold below which CNS manifestations seldom, or only very slowly, develop. Therefore, it may be useful as a tentative treatment goal for ERT in reducing or maintaining HS levels.

![Figure 6](https://example.com/figure6.png)

**Figure 6.** Baseline HS concentrations in the CSF of the 29 patients in the phase II/III clinical trial of pabinafusp alfa

Figure 7 shows the changes in the HS levels in the CSF of all 39 patients in the phase II/III study in Japan, the phase II study in Brazil and the respective extention studies. The data are presented with respect to their MPS subtypes (severe or attenuated) and all patients had received pabinafusp alfa for 104 weeks at either 2.0 or 4.0mg/kg. In the
2.0 mg/kg group in the phase II and phase II/III studies, HS concentrations in the CSF significantly decreased between week 1 and week 26 (p<0.001), with a difference of −3366±1923 ng/mL (relative changes from week 1 to week 26: −57.655±11.500%). HS concentrations in the CSF decreased in all subjects in both groups. Notably, the treatment reduced the CSF HS levels in the majority of the patients to below the threshold level of 4000 ng/ml.

![Graph showing HS concentrations over weeks](image)

**Figure 7.** Reductions in the HS concentrations in the CSF of patients with the severe and attenuated subtypes of MPS II in the phase II and II/III studies.

2) Neurocognitive efficacy

In the studies carried out in Japan, neurocognitive development was evaluated according to the Kyoto Scale of Psychological Development (KSPD). This corresponds to the Bayley scales of infant and toddler development, third edition (BSID-III), which was employed for the patients in Brazil with developmental ages younger than 42 months (age-equivalent [AE] scores), while the Kaufman Assessment Battery for Children, 2nd edition (KABCII), was used for the older patients.

Figure 8 shows the changes in AE scores in the patients with the severe subtype of MPS-II in the phase II and II/III studies, overlayed onto those from the natural history data on Japanese patients with the severe subtype [28]. Almost all of the patients in Brazil showed marked improvement in AE scores over 104 weeks, while most of the Japanese patients showed stabilization, along with improvement in some.
Figure 8. Age equivalent scores in the phase II and phase II/III studies in patients with the severe subtype of MPS-II, overlayed onto the corresponding developmental trajectories from the natural history data. JR-141-BR21/BR22 stands for the phase II study in Brazil and its extension study; JR-141-301/302 indicates the phase II/III study in Japan and its extension study.

Table 1 numerically substantiates these AE score changes in patients with both the attenuated and severe subtypes. At week 52, improvement or stabilization in terms of AE score changes were observed in 85% of the patients with the two subtypes in Japan, and 94% of those in Brazil. At week 104, 62% of the patients in Japan and 75% of those in Brazil showed improvement or stabilization. Taken together, these results show that pabinafusp alfa brought about improvements or stabilization of neurocognitive impairment in 89% of the patients with MPS-II irrespective of their subtypes at week 52, and in 75% of them at week 104.
Table 1. Changes in AE scores on KSPD (for Japan), BSID-III and KABCII (for Brazil). Changes in AE scores exceeding 3 months were defined as improvement, while those ± 3 months as stabilization, and those below 3 months as deterioration, respectively.

<table>
<thead>
<tr>
<th></th>
<th>Deterioration</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>6(40%)</td>
<td></td>
<td>6(38%)</td>
<td>2(17%)</td>
<td>0</td>
<td>2(12%)</td>
</tr>
</tbody>
</table>

In addition to the standardized neurocognitive assessments, clinical behavioral observations by the subjects’ families and investigators were collected in order to register subtle but potentially meaningful behavioral changes that the standardized assessments might fail to capture, in particular in patients with the advanced severe subtype (detailed tabulated reports of the narrative records are published elsewhere[14, 15]).

In both the phase II/III and II studies, similar behavioral changes were observed across 3 major areas (speech, motor functions and liveliness/expression). Positive behavioral changes in speech included increased utterances, better verbal responsiveness and resumption of singing. In terms of liveliness/expression, stable mood, less agitation and more smiling were often reported. These positive changes were observed across all ages and subtypes, although the younger subjects showed more marked improvements than the older ones. Notably, even among the subjects without marked improvements in speech or motor functions (especially the adult subjects with a long history of disease), positive changes in important attachment behaviors (e.g. smiling) [29] were still recognizable.

The fact that these subjective, non-standardized observations are in accordance with the objective findings from the neurodevelopmental scales seems to further buttresses the neurocognitive efficacy of pabinafusp alfa across all patient populations with different ages and subtypes.

3) Somatic efficacy

As a measure of the efficacy of pabinafusp alfa against the somatic symptoms of MPS II, liver and spleen volumes are reported here as representative efficacily endpoints, because progressive hepatosplenomegaly is a prominent clinical feature of the disease. In evaluating the changes in organomegaly, attention needs to be paid to the large variability in organ volumes in pediatric subjects, so individual subjects’ relative volume changes at week 52, with the baseline volume taken as 100%. The liver and spleen volumes significantly decreased in the naïve patients without prior ERT, and they also decreased by about 5 % in the patients who were switched from conventional ERT to pabinafusp alfa (Table 2, Figure 9).
Figure 9. Relative changes in the liver and spleen volumes from baseline to week 52. The blue dotted lines are suggested thresholds of clinically significant changes (10% for liver volume and 20% for spleen volume), and values below these can be interpreted as either stabilization or improvement of hepatosplenomegaly.

<table>
<thead>
<tr>
<th>ERT status</th>
<th>N</th>
<th>Mean (SD)</th>
<th>Median [min-max]</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver volume</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Switched subjects</td>
<td>28</td>
<td>-5.4 (13.3)</td>
<td>-6.0 [-38.0 - 23.4]</td>
<td>-10.6 - -0.2</td>
</tr>
<tr>
<td>Naïve subjects</td>
<td>4</td>
<td>-30.8 (6.5)</td>
<td>-31.1 [-38.4 - 22.6]</td>
<td>-41.2 - -20.4</td>
</tr>
<tr>
<td>Spleen volume</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Switched subjects</td>
<td>28</td>
<td>-4.3 (19.7)</td>
<td>-3.7 [-62.2 - 31.6]</td>
<td>-11.9 - 3.4</td>
</tr>
<tr>
<td>Naïve subjects</td>
<td>4</td>
<td>-32.3 (6.7)</td>
<td>-33.3 [-38.7 - 23.8]</td>
<td>-42.9 - -21.6</td>
</tr>
</tbody>
</table>

Table 2. Liver and spleen volumes
These results, along with other somatic efficacy data (e.g., changes in serum HS and DS concentrations and cardiac function [14, 15]), suggest that the efficacy of pabinafusp alfa against somatic symptoms is comparable to that of conventional idursulfase.

2.3.2 Clinical safety data

The safety of pabinafusp alfa was evaluated on the basis of the results of the phase I/II, II, and II/III studies, and safety was confirmed in the patients in the 1.0, 2.0, and 4.0 mg/kg groups. The optimal weekly dose of pabinafusp alfa was considered to be 2.0 mg/kg, because most of the adverse drug reactions (ADRs) in this group were mild and all duly managed without patients having to withdraw from the study. A summary of the clinical safety of pabinafusp alfa is shown in Table 3. Of note is the fact that no dose-limiting toxicities were observed at 4.0 mg/kg in the phase II study in Brazil, even though the infusion-associated reaction (IARs) were observed most frequently at this dose.

<table>
<thead>
<tr>
<th></th>
<th>Phase I/II study in Japan</th>
<th>Phase II/III study in Japan</th>
<th>Phase II study in Brazil</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Proportion (%)</td>
<td>Number of events</td>
<td>N</td>
</tr>
<tr>
<td>Number of subjects</td>
<td>14</td>
<td>--</td>
<td>--</td>
<td>28</td>
</tr>
<tr>
<td>Adverse events</td>
<td>9</td>
<td>64.3</td>
<td>20</td>
<td>28</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>1</td>
<td>7.1</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>(Deaths)</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Significant adverse events</td>
<td>4</td>
<td>28.6</td>
<td>8</td>
<td>17</td>
</tr>
<tr>
<td>(Infusion associated reaction)</td>
<td>4</td>
<td>28.6</td>
<td>8</td>
<td>14</td>
</tr>
<tr>
<td>Adverse drug reactions</td>
<td>7</td>
<td>50.0</td>
<td>11</td>
<td>15</td>
</tr>
<tr>
<td>Serious adverse drug reactions</td>
<td>1</td>
<td>7.1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>(Deaths)</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Significant adverse drug reactions</td>
<td>4</td>
<td>28.6</td>
<td>8</td>
<td>14</td>
</tr>
<tr>
<td>(Infusion associated reaction)</td>
<td>4</td>
<td>28.6</td>
<td>8</td>
<td>14</td>
</tr>
</tbody>
</table>

Table 3. Summary of adverse events and adverse drug reactions for pabinafusp alfa in the phase II/III and II studies

There were 11 non-fatal serious adverse events in the three studies, none of which were related to pabinafusp alfa. Both of the two reported deaths were due to respiratory
failure as an exacerbation of MPS-II and unrelated to the drug. In summary, pabinafasp alfa was found to be generally well tolerated at doses of up to 4mg/kg, and its long-term safety up to 104 weeks has been confirmed as acceptable.

Discussion

To date, pabinafusp alfa is the first and only recombinant enzyme that can be successfully delivered via intravenous administration across the BBB. It also demonstrated clinically meaningful efficacy against the CNS symptoms of MPS-II, whilst also showing efficacy against the somatic symptoms. Establishment of this novel IV ERT with both central and peripheral efficacy has overcome formidable challenges.

Despite the fairly straightforward basic pathophysiology of neuronopathic MPS which starts with a genetic enzyme deficiency that leads to the accumulation of uncatabolized substrates in the CNS and progressive neurodegeneration, details of the functional and structural neuronal damages it causes remain yet to be elucidated [3]. To try to unravel the complexities behind this pathogenesis and progression, we took a three-pronged approaches. First, we evaluated the initial component of the pathogenesis (i.e. substrate accumulation) by measuring HS concentrations in the brain and the CSF. Second, we carried out histopathological evaluations to investigate the neurodegeneration, the second component. And third, we examined behavioral abnormalities as representing CNS manifestations, thereby capturing the final component of the neurodegenerative events.

The systemic GAG accumulations in our MPS II mouse model were reduced dose-dependently by intravenous administration of pabinafusp alfa (2.1.2), which then duly suppressed neuroinflammation and other neuropathological abnormalities (2.1.3), leading to normalization of impaired spatial learning abilities (2.1.4). These preclinical findings corroborated the efficacy of pabinafusp alfa through all three components of the pathogenesis of the neuronopathy, and encouraged translation of these findings into clinical studies.

We found that the extent of damages to the CNS and its manifestations in MPS II mice were not solely determined by the HS concentrations in the brain, but also by the duration of HS elevation [22], suggesting a cumulative pathogenicity of intracerebral HS accumulation. It was clear, therefore, that temporal factors must be taken into account to better address the onset and progression of neurodegeneration (Figure 10) [22]. This underpins the importance of early introduction of ERT for patients with neuronopathic MPS-
II, so that the period of elevated HS levels in the brain is shortened to prevent or ameliorate neurocognitive impairment in future. Indeed, our 104-week neurodevelopmental data show almost normal developmental trajectories in some of the very young patients given pabinafusp alfa, unlike the older patients (Figure 8). This point is poignantly exemplified by the markedly divergent developmental trajectories of two siblings with MPS-II, one treated with conventional ERT and the other from early on with pabinafusp alfa [30].

![Diagram](Image)

**Figure 10.** Conceptual association between cumulative exposure of the brain to HS and CNS disease progression in patients with neuronopathic MPS II. The vertical dashed arrows indicate the presumed timings of the onset of neuronopathic events. The Y-intercepts with dashed lines indicate the postulated levels of cumulative exposure of the brain to HS when a corresponding neuropathology evolves. The red and blue lines indicate the cumulative exposures to HS in patients with MPS II and healthy subjects, respectively. Early intervention with pabinafusp alfa decreases the intracerebral HS concentrations and thereby reduces the cumulative exposure, preventing or delaying the onset of CNS involvement. Even if the treatment starts when some symptoms have already developed, clearance of HS accumulations in the brain may be able to reverse the symptoms by correcting neuronal dysfunctions before the advent of irreversible (mostly structural) CNS damage occurs.

The development of novel therapeutics for a rare disease invariably involves a dilemma: balancing the difficulty of evaluating the drug’s efficacy against a disease that is
perhaps not fully understood and with few patients available for clinical trials on the one hand with the requirement to expedite development to meet urgent medical needs on the other. MPS-II is known to be a heterogeneous yet progressive, debilitating, and often fatal disease. While long-term functional and structural assessments would have provided more robust efficacy data, we had to make a realistic compromise had to be made to advance the development of pabinafusp alfa by capturing both the biochemical surrogate endpoints and the clinical endpoints reflecting CNS manifestations. In other words, this study examined both the initial process of neurodegeneration and, at the same time, some of the clinical neuropsychiatric manifestations as the final outcome of the long and complex pathological process. Limitations in the reported clinical studies, in particular in respect to the long-term neurodevelopmental data, need to be addressed in post-marketing studies in Japan and the planned phase III global trial, which will provide further evidence of the dual efficacy of pabinafusp alfa against both somatic and CNS symptoms in patients with MPS-II.

4. Materials and Methods

4.1. Preclinical studies

4.1.1. Animals

hTfR-KI/Ids-KO mice, a mouse model of MPS II, were established as described previously [11], and C57BL/6 mice (Charles River, Japan) were used as a normal control. The cynomolgus monkeys (Macaca fascicularis) used had all been purpose-bred for research. All animal experiments were conducted under the approval of the Animal Care and Use Committees of Shin Nippon Biomedical Laboratories, Nihon Bioresearch, and JCR Pharmaceuticals.

4.1.2. BBB penetration

Brain delivery of pabinafusp alfa by BBB penetration was determined by immunohistochemical analysis in cynomolgus monkeys that had received intravenous infusion of the drug at 5 mg/kg. Pabinafusp alfa was detected with an HRP-labeled human IgG antibody. Detailed methods are described elsewhere [11].

4.1.3. Substrate reduction
To evaluate the efficacy of pabinafusp alfa in reducing substrate accumulations, the drug was administered to MPS II mice through the tail vein at a 2 mg/kg once a week for 1, 4, 8, 12, or 36 weeks. Control mice were given idursulfase at 0.5 mg/kg once a week. One week after the final dosing, tissues and organs including the brain and CSF were collected so that HS concentrations could be measured by liquid chromatography-tandem mass spectrometry [12].

4.1.4. Evaluation of neuroinflammation and neurodegeneration

Pabinafusp alfa was intravenously administered to MPS II mice at 2 mg/kg once a week for 36 weeks. One week after the final dosing, tissues and organs were collected and the brains were subjected to histopathological analysis [22]. Expression of GFAP was used as a marker for activation of the astrocytes, and expression of CD68 as a maker for the activation of microglial cells. Staining with hematoxylin and eosin was performed to detect morphological changes in neuronal cells.

4.1.5. Evaluation of neurocognitive abnormalities

The Morris water maze test was used to examine spatial learning ability was performed after 36-week treatment. Briefly, each mouse was placed with its head facing the wall of a circular pool equipped with a transparent acrylic resin platform, and the time taken to reach the platform (goal latency) was measured [22].

4.1.6. Safety

Safety evaluations using in vitro assays in cynomolgus monkeys were carried out as previously described [19].

4.2. Clinical studies

The study designs, procedures, outcomes, statistical analyses and other details of the three clinical trials of pabinafusp alfa are summarised in Appendix A.

5. Conclusions
This article summarizes and updates our preclinical and clinical evidence of the dual efficacy of pabinafusp alfa against both the central and peripheral/somatic symptoms of neuronopathic MPS-II. The drug’s mechanism of action has been highlighted: intravenously administered IDS is delivered to the body via M6P- and TfR-mediated transcytoses, and into the brain parenchyma via TfR-mediated transcytosis. By reducing HS accumulations in the brain, pabinafusp alfa prevents or alleviates neurodegeneration. Further long-term data on more patients is expected to provide further evidence of the benefits of this novel drug, and we hope that its mechanism of action can in due course be applied to treat other neuronopathic lysosomal storage diseases, so that their hitherto unaddressed CNS manifestations can also be better managed.

**Author Contributions:**
Conceptualization, K.T and H.S.; methodology, H.M., K.M., T.Y. and S.S.; formal analysis, M.Y. and T.I; investigation, R.G., A.M.M., T.O., Y.E., N.S., K.N. and K.M.; writing—original draft preparation, K.M. and Y.S.; writing—review and editing, Y.S. and M.S.;; supervision, K.T., H.S. and M.S.; project administration, T.Y. and S.S. All authors have read and agreed to the published version of the manuscript.

**Funding:**
This research was funded by JCR Pharmaceuticals.

**Institutional Review Board Statement:**
The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Boards of the 21 participating investigational sites. The names of the sites and the IRBs, identification code of the study, and the approved dates are given in Appendix B

**Informed Consent Statement:**
All patients or their legal guardians submitted a signed, informed consent form prior to enrolment in the study. The blank informed consent documents for the studies are also attached as Appendix C.

**Data Availability Statement:**
The data presented in this study may be available on request from the corresponding author. The data are not publicly available due to the intellectual property rights for pabinafusp alfa.

**Acknowledgments:**
The authors are grateful to all investigators, sub-investigators, study coordinators, the clinical research team, and patients involved for their contribution and commitment to the study. The helpful suggestions and guidance of Elsa Shapiro of the University of Minnesota, Minneapolis, on the neurodevelopmental assessment are greatly appreciated. We also thank Maiko Kokado, Naoko Takasao, Minako Kobayashi, Ryo Ibaraki, Ami Kamitani, Kohtaro Hamauchi, Yukimichi Nakano and Saki Yasui of JCR Pharmaceuticals for their support at various stages of the study. Special thanks are due to Timothy Minton of Keio University, Tokyo, for his immense editorial help.

Conflicts of Interest:
R.G. has been an investigator, consultant, and/or speaker within the last 12 months for Abeona, Allevex, Amicus, Azafaros, BioMarin, Chiesi, Cyclo, DASA/GENEONE, Denali, Idorsia, Inventiva, JCR, Lysogene, Novartis, Paradigm, PassageBio, PTC, RegenxBio, Sanofi-Genzyme, Sigilon, Sobi, Takeda, and Ultragenyx. A.M.M. has received honoraria and support for travelling to congresses from BioMarin, Sanofi Genzyme, Takeda, and Ultragenyx. A.M.M. has received research fundings from Alexion, BioMarin, Sanofi Genzyme, and Takeda. T.O. has conducted consultancy for JCR Pharmaceuticals and reports research grants from BioMarin Pharmaceutical, Green Cross, Sanofi, Takeda, and JCR Pharmaceuticals. Y.E. has conducted consultancy for JCR Pharmaceuticals, and he has been awarded grants and research support from Actelion, BioMarin Pharmaceutical, and Sanofi; he has also received honoraria from Actelion, BioMarin Pharmaceutical, Sanofi, Takeda, and Dainippon Sumitomo Pharma. N.S. has conducted consultancy for JCR Pharmaceuticals, and he has been awarded grant/research support from Sanofi and Dainippon Sumitomo Pharma and honoraria from Actelion, BioMarin Pharmaceutical, Sanofi, Shire, and Dainippon Sumitomo Pharma. K.N. has conducted consultancy for JCR Pharmaceuticals. H.M., K.M., T.Y., M.Y., T.I., S.S., K.T. and Y.S. are employed by JCR Pharmaceuticals, of which H.S. and M.S. are board members.

Appendix A (attached)

Appendix B (attached)

Appendix C (attached)

References


